Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:LNTH NYSE:MDT NYSEARCA:MDY NYSE:SYK NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.26-0.1%$26.81$19.05▼$32.56$3.83B0.723.51 million shs1.99 million shsLNTHLantheus$103.00+9.0%$83.62$47.25▼$103.89$6.71B-0.081.04 million shs2.02 million shsMDTMedtronic$78.66+0.7%$83.50$74.40▼$106.33$100.91B0.6210.01 million shs7.05 million shsMDYSPDR S&P MidCap 400 ETF Trust$670.65+0.8%$644.32$537.75▼$685.50$26.35B1.021.02 million shs729,943 shsSYKStryker$316.39+0.9%$325.22$281.00▼$404.87$121.33B0.82.99 million shs1.89 million shsTMDXTransMedics Group$68.93+0.1%$98.18$60.10▼$156.00$2.38B2.071.92 million shs1.15 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%+0.26%+12.93%+28.64%+28.54%LNTHLantheus0.00%+9.68%+24.37%+39.43%+37.10%MDTMedtronic0.00%+3.34%-6.14%-18.81%-6.94%MDYSPDR S&P MidCap 400 ETF Trust0.00%+1.72%+1.15%+1.83%+22.78%SYKStryker0.00%+3.15%-4.02%-16.77%-16.74%TMDXTransMedics Group0.00%+9.07%-39.11%-48.66%-43.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.26-0.1%$26.81$19.05▼$32.56$3.83B0.723.51 million shs1.99 million shsLNTHLantheus$103.00+9.0%$83.62$47.25▼$103.89$6.71B-0.081.04 million shs2.02 million shsMDTMedtronic$78.66+0.7%$83.50$74.40▼$106.33$100.91B0.6210.01 million shs7.05 million shsMDYSPDR S&P MidCap 400 ETF Trust$670.65+0.8%$644.32$537.75▼$685.50$26.35B1.021.02 million shs729,943 shsSYKStryker$316.39+0.9%$325.22$281.00▼$404.87$121.33B0.82.99 million shs1.89 million shsTMDXTransMedics Group$68.93+0.1%$98.18$60.10▼$156.00$2.38B2.071.92 million shs1.15 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%+0.26%+12.93%+28.64%+28.54%LNTHLantheus0.00%+9.68%+24.37%+39.43%+37.10%MDTMedtronic0.00%+3.34%-6.14%-18.81%-6.94%MDYSPDR S&P MidCap 400 ETF Trust0.00%+1.72%+1.15%+1.83%+22.78%SYKStryker0.00%+3.15%-4.02%-16.77%-16.74%TMDXTransMedics Group0.00%+9.07%-39.11%-48.66%-43.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.63Moderate Buy$32.172.90% UpsideLNTHLantheus 2.73Moderate Buy$99.71-3.19% DownsideMDTMedtronic 2.58Moderate Buy$106.4535.33% UpsideMDYSPDR S&P MidCap 400 ETF Trust 2.78Moderate Buy$670.65N/ASYKStryker 2.73Moderate Buy$395.4825.00% UpsideTMDXTransMedics Group 2.50Moderate Buy$135.0095.85% UpsideCurrent Analyst Ratings BreakdownLatest LNTH, TMDX, MDT, SYK, CPRX, and MDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026MDTMedtronic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/21/2026MDTMedtronic The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$84.005/21/2026MDTMedtronic The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$84.005/18/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026CPRXCatalyst Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.005/8/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$95.00 ➝ $100.005/7/2026LNTHLantheus The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$94.005/7/2026CPRXCatalyst Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$588.99M6.50$2.92 per share10.69$8.27 per share3.78LNTHLantheus$1.54B4.35$6.39 per share16.13$18.62 per share5.53MDTMedtronic$33.54B3.01$7.76 per share10.14$37.62 per share2.09MDYSPDR S&P MidCap 400 ETF TrustN/AN/AN/AN/AN/AN/ASYKStryker$25.12B4.83$16.88 per share18.74$59.94 per share5.28TMDXTransMedics Group$635.89M3.75$3.93 per share17.55$14.29 per share4.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.7417.9710.150.9137.08%35.76%31.31%8/5/2026 (Estimated)LNTHLantheus$233.56M$4.1524.8219.18N/A18.05%29.32%15.00%8/5/2026 (Estimated)MDTMedtronic$4.66B$3.5921.9112.941.8713.00%14.82%7.88%6/3/2026 (Estimated)MDYSPDR S&P MidCap 400 ETF TrustN/AN/A18.98N/AN/AN/AN/AN/AN/ASYKStryker$3.25B$8.6436.6219.031.9913.20%23.42%11.04%7/30/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.6718.99N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest LNTH, TMDX, MDT, SYK, CPRX, and MDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q4 2026MDTMedtronic$1.56N/AN/AN/A$9.62 billionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million4/30/2026Q1 2026SYKStryker$2.98$2.60-$0.38$1.93$6.34 billion$6.02 billion2/26/2026Q4 2025LNTHLantheus$1.17$1.67+$0.50$0.82$367.03 million$406.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMDTMedtronic$2.843.61%+5.33%79.11%49 YearsMDYSPDR S&P MidCap 400 ETF Trust$7.121.06%N/AN/AN/ASYKStryker$3.521.11%+7.58%40.74%32 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest LNTH, TMDX, MDT, SYK, CPRX, and MDY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/6/2026SYKStrykerquarterly$0.881.2%6/30/20266/30/20267/31/20263/5/2026MDTMedtronicquarterly$0.713.26%3/27/20263/27/20264/17/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A7.106.84LNTHLantheus0.472.832.64MDTMedtronic0.572.541.87MDYSPDR S&P MidCap 400 ETF TrustN/AN/AN/ASYKStryker0.622.111.25TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%LNTHLantheus99.06%MDTMedtronic82.06%MDYSPDR S&P MidCap 400 ETF TrustN/ASYKStryker77.09%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%LNTHLantheus1.70%MDTMedtronic0.26%MDYSPDR S&P MidCap 400 ETF TrustN/ASYKStryker4.60%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.38 million109.65 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableMDTMedtronic95,0001.28 billion1.28 billionOptionableMDYSPDR S&P MidCap 400 ETF TrustN/A39.29 millionN/ANot OptionableSYKStryker56,000383.36 million365.73 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableLNTH, TMDX, MDT, SYK, CPRX, and MDY HeadlinesRecent News About These CompaniesHead to Head Comparison: TransMedics Group (NASDAQ:TMDX) vs. Pressure BioSciences (OTCMKTS:PBIO)May 22 at 4:49 AM | americanbankingnews.comTransMedics Shareholders Reelect Board and Approve Executive PayMay 21 at 6:30 PM | tipranks.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 21 at 4:05 PM | prnewswire.comTransMedics Group Signals Growth Amid Margin SqueezeMay 21 at 12:15 PM | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Gains Momentum In Healthcare SpaceMay 19, 2026 | kalkinemedia.comKTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceMay 19, 2026 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Shares Up 7.1% - Here's What HappenedMay 18, 2026 | marketbeat.comTransMedics Group (TMDX) price target decreased by 22.22% to 126.07May 14, 2026 | msn.comTransMedics Group (NASDAQ:TMDX) Reaches New 52-Week Low - Here's WhyMay 12, 2026 | marketbeat.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11, 2026 | finance.yahoo.comWall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to SellMay 9, 2026 | marketbeat.comTransMedics Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comTransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...May 8, 2026 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comTransMedics Group (TMDX) Gets a Buy from NeedhamMay 7, 2026 | theglobeandmail.comTransMedics Group Stock Watch: Healthcare Growth in FocusMay 6, 2026 | kalkinemedia.comKTransMedics tumbles after earnings missMay 6, 2026 | seekingalpha.comTransMedics: Cheaper, But Still Priced For PerfectionMay 6, 2026 | seekingalpha.comTransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity GroupMay 6, 2026 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD CowenMay 6, 2026 | marketbeat.comStifel Nicolaus Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $85.00May 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLNTH, TMDX, MDT, SYK, CPRX, and MDY Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.26 -0.02 (-0.06%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$31.22 -0.04 (-0.11%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Lantheus NASDAQ:LNTH$103.00 +8.53 (+9.03%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$101.75 -1.25 (-1.21%) As of 05/22/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Medtronic NYSE:MDT$78.66 +0.51 (+0.65%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$78.60 -0.06 (-0.08%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.SPDR S&P MidCap 400 ETF Trust NYSEARCA:MDY$670.65 +5.40 (+0.81%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$670.06 -0.59 (-0.09%) As of 05/22/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SPDR S&P MidCap 400 ETF is an exchange traded fund. SPDR MidCap 400 Trust focuses to correspond to the price and yield performance of the S&P MidCap 400 Index. The S&P MidCap 400 covers over 7% of the United States equities market, and is part of a series of S&P the United States indices. The index also includes companies, which should have four consecutive quarters of positive as-reported earnings, excluding discontinued operations and extraordinary items. Its investment sectors include financials, industrials, information technology, consumer discretionary, healthcare and materials. Bank of New York acts as an investment manager.Stryker NYSE:SYK$316.39 +2.89 (+0.92%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$316.50 +0.11 (+0.03%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.TransMedics Group NASDAQ:TMDX$68.93 +0.08 (+0.12%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$68.53 -0.40 (-0.58%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
